Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 1/2013

01-01-2013 | Original Article

Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia—a randomized placebo-controlled trial

Authors: R. D. Chapurlat, M. Laroche, T. Thomas, S. Rouanet, P. D. Delmas, M.-C. de Vernejoul

Published in: Osteoporosis International | Issue 1/2013

Login to get access

Abstract

Summary

We have examined the effect of oral monthly ibandronate on distal radius and tibia microarchitecture with high-resolution peripheral quantitative tomography compared with placebo, in women with osteopenia, and found that ibandronate did not significantly affect trabecular bone but improved cortical density and thickness at the tibia.

Methods

We have examined the effect of ibandronate on bone microarchitecture with peripheral high-resolution quantitative computed tomography (HR-pQCT) in a randomized placebo-controlled trial among 148 women with osteopenia. Patients received either oral 150 mg monthly ibandronate or placebo over 24 months. Bone microarchitecture was assessed at baseline, 6, 12, and 24 months, using HR-pQCT at the distal radius and tibia; areal bone mineral density (aBMD) was measured with DXA at the spine, hip, and radius.

Results

At 12 months, there was no significant difference in trabecular bone volume at the radius (the primary end point) between women on ibandronate (10.8 ± 2.5%) and placebo (10.5 ± 2.9%), p = 0.25. There was no significant difference in other radius trabecular and cortical microarchitecture parameters at 12 and 24 months. In contrast, at the tibia, cortical vBMD in the ibandronate group was significantly greater than in the placebo group at 6, 12, and 24 months, with better cortical thickness at 6, 12, and 24 months. With ibandronate, aBMD was significantly increased at the hip and spine at 12 and 24 months but at the radius was significantly superior to placebo only at 24 months. Most of the adverse events related to ibandronate were expected with bisphosphonate use, and none of them were serious.

Conclusion

We conclude that 12 months of treatment with ibandronate in women with osteopenia did not affect trabecular bone microarchitecture, but improved cortical vBMD at the tibia at 12 and 24 months, and preserved cortical thickness at the tibia.
Literature
1.
Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: result from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMedCrossRef
2.
Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 16:1184–1192
3.
Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2006) In vivo assessment of trabecular bone microarchitecture by high resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90:6508–6515CrossRef
4.
Majumdar S, Genant HK, Grampp S et al (1997) Correlation, of trabecular bone structure with age, bone mineral density, and osteoporotic status: in vivo studies in the distal radius using high resolution magnetic resonance imaging. J Bone Miner Res 12:111–118PubMedCrossRef
5.
Sornay-Rendu E, Cabrera-Bravo JL, Boutroy S, Munoz F, Delmas PD (2009) Severity of vertebral fractures is associated with alterations of cortical architecture in postmenopausal women. J Bone Miner Res 24:737–743PubMedCrossRef
6.
Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD (2007) Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res 22:425–433PubMedCrossRef
7.
Melton LJ III, Riggs BL, Keaveny TM, Achenbach SJ, Kopperdahl D, Camp JJ, Rouleau PA, Amin S, Atkinson EJ, Robb RA, Therneau TM, Khosla S (2010) Relation of vertebral deformities to bone density, structure and strength. J Bone Miner Res 25:1922–1930PubMedCrossRef
8.
Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 34:599–604PubMedCrossRef
9.
Chapurlat RD, Ramsay P, Palermo L, Cummings SR (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16:842–848PubMedCrossRef
10.
Gordon CL, Lang TF, Augat P, Genant HK (1998) Image-based assessment of spinal trabecular bone structure from high-resolution CT images. Osteoporos Int 8:317–325PubMedCrossRef
11.
Link TM, Vieth V, Langenberg R et al (2003) Structure analysis of high resolution magnetic resonance imaging of the proximal femur: in vitro correlation with biomechanical strength and BMD. Calcif Tissue Int 72:156–165PubMedCrossRef
12.
Chesnut CH 3rd, Rosen CJ (2003) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163–2172CrossRef
13.
Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11–14PubMedCrossRef
14.
Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S (2010) A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res 25:2558–2571PubMedCrossRef
15.
Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886–1894PubMedCrossRef
16.
Seeman E, Chapurlat R, Cheung A, Felsenberg D, Laroche M, Reeve J, Thomas T, Zanchetta J, Bock O, Morris E, Tile L, D’Alo G, Darbie L, Borah B, Rizzoli R (2010) Risedronate reduces microstructural deterioration of cortical bone accompanying menopause. Osteoporos Int 21(Suppl1):S9
17.
Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM (2007) Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 41:290–296PubMedCrossRef
18.
Braith RW, Conner JA, Fulton MN, Lisor CF, Casey DP, Howe KS, Baz MA (2007) Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant 26(2):132–137PubMedCrossRef
19.
Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694PubMedCrossRef
20.
Boyd SK (2008) Site-specific variation of bone micro-architecture in the distal radius and tibia. J Clin Densitom 11:424–430PubMedCrossRef
21.
Davis KA, Burghardt AJ, Link TM, Majumdar S (2007) The effects of geometric and threshold definitions on cortical bone metrics assessed by in vivo high-resolution peripheral quantitative computed tomography. Calcif Tissue Int 81:364–371PubMedCrossRef
Metadata
Title
Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia—a randomized placebo-controlled trial
Authors
R. D. Chapurlat
M. Laroche
T. Thomas
S. Rouanet
P. D. Delmas
M.-C. de Vernejoul
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 1/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-1947-4

Other articles of this Issue 1/2013

Osteoporosis International 1/2013 Go to the issue

Original Article

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Original Article

Vitamin D2 from light-exposed edible mushrooms is safe, bioavailable and effectively supports bone growth in rats

Short Communication

Ten-year hip fracture incidence rate trends in a large California population, 1997–2006

Review

Life-course evidence of birth weight effects on bone mass: systematic review and meta-analysis

Original Article

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

Original Article

Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study